Skip to main content

Bristol Myers Squibb Revlimid revenue

  • BMY · NYSE
  • Pharmaceuticals
  • S&P 500
$63.43+1.78%Close 13 Nov 2026 · Market value $128.9B

Revlimid revenue at Bristol Myers Squibb came to $303.0M for the quarter to 30 Sep 2026, down 47.3% from a year earlier.

As Bristol Myers Squibb reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 29 Oct 2026.

By quarter

$1.5BDec 2023$1.7BMar 2024$1.4BJun 2024$1.4BSep 2024$1.3BDec 2024$936.0MMar 2025$838.0MJun 2025$575.0MSep 2025$602.0MDec 2025$349.0MMar 2026$425.0MJun 2026$303.0MSep 2026
Bristol Myers Squibb Revlimid revenue, every reported period
Period endingRevlimid revenueChange on a yearFiled
30 Sep 2026$303.0Mdown 47.3%29 Oct 2026
30 Jun 2026$425.0Mdown 49.3%30 Jul 2026
31 Mar 2026$349.0Mdown 62.7%30 Apr 2026
31 Dec 2025$602.0Mdown 55.0%11 Feb 2026
30 Sep 2025$575.0Mdown 59.3%30 Oct 2025
30 Jun 2025$838.0Mdown 38.1%31 Jul 2025
31 Mar 2025$936.0Mdown 43.9%24 Apr 2025
31 Dec 2024$1.3Bdown 7.7%12 Feb 2025
30 Sep 2024$1.4Bdown 1.2%31 Oct 2024
30 Jun 2024$1.4Bdown 7.8%26 Jul 2024
31 Mar 2024$1.7Bdown 4.6%25 Apr 2024
31 Dec 2023$1.5Bdown 35.8%13 Feb 2024
30 Sep 2023$1.4Bdown 41.0%26 Oct 2023
30 Jun 2023$1.5Bdown 41.3%27 Jul 2023
31 Mar 2023$1.8Bdown 37.4%27 Apr 2023
31 Dec 2022$2.3Bdown 32.1%14 Feb 2023
30 Sep 2022$2.4Bdown 27.7%26 Oct 2022
30 Jun 2022$2.5Bdown 21.9%27 Jul 2022
31 Mar 2022$2.8Bdown 5.0%29 Apr 2022
31 Dec 2021$3.3Bup 1.5%9 Feb 2022
30 Sep 2021$3.3Bup 10.6%27 Oct 2021
30 Jun 2021$3.2Bup 11.0%28 Jul 2021
31 Mar 2021$2.9Bup 1.0%29 Apr 2021
31 Dec 2020$3.3Bup 152.5%10 Feb 2021
30 Sep 2020$3.0B—5 Nov 2020
30 Jun 2020$2.9B—6 Aug 2020
31 Mar 2020$2.9B—7 May 2020
31 Dec 2019$1.3B—24 Feb 2020
30 Sep 2019$0—31 Oct 2019
30 Jun 2019$0—25 Jul 2019
31 Mar 2019$0—25 Apr 2019

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Bristol Myers Squibb: International revenues · Gross product sales · Net product sales · Growth Portfolio revenue · Legacy Portfolio revenue · Eliquis revenue · Opdivo revenue · Orencia revenue · Yervoy revenue · Reblozyl revenue · Breyanzi revenue · Alliance and other revenues · Camzyos revenue · Opdualag revenue · Opdivo Qvantig revenue · Zeposia revenue · Pomalyst/Imnovid revenue · Abecma revenue · Sotyktu revenue · Alliance revenues · Sprycel revenue · Abraxane revenue · Krazati revenue · Cobenfy revenue · financial statements

Every KPI and segment of BMY, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.